SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Home » Investors » Corporate Governance » Committees to the Board
The Board has constituted various committees to focus on specific areas and to make informed decisions within their authority. Each committee is governed by its charter, which outlines the scope, roles, responsibilities and powers of the committee. All the decisions and recommendations of the committees are placed before the Board for its noting and approval.
The Board, on October 19, 2011, constituted the Audit and Risk Committee. At its meeting held on January 22, 2019, the Board has constituted an independent Risk Management Committee. Therefore, the Audit and Risk Committee was renamed as Audit Committee. The Audit Committee comprises of the following board members:
Ms. Sharmila Abhay Karve, Chairperson, Lead Independent Director
Mr. Suresh Narayanan,Independent Director
Ms. Vinita Bali, Non-Executive Director
Mr. Nilanjan Roy, Independent Director
The Nomination and Remuneration Committee reviews, acts on and reports to the Board with respect to various governance, nomination, compensation and performance evaluation matters. The Committee works with full autonomy and is free of any managerial interference. The Committee comprises of the following board members:
Mr. Suresh Narayanan, Chairperson, Independent Director
Prof. Catherine Rosenberg, Non-Executive Director
Ms. Sharmila Karve, Lead Independent Director
Ms. Vinita Bali, Non-Executive Director
Dr. Arun Chandavarkar, Independent Director
Ms. Manja Boerman, Independent Director
Mr. Sanjaya Singh, Independent Director
In terms of Section 135 of the Companies Act, 2013, the Board has constituted the Corporate social responsibility (CSR) Committee. The CSR Committee comprises of the following board members:
Prof. Catherine Rosenberg, Chairperson, Non-Executive Director
Ms. Vinita Bali, Non-Executive Director
Mr. Sanjaya Singh, Independent Director
Ms. Sharmila Karve, Lead Independent Director
The Stakeholders Relationship Committee comprises of the following board members:
Mr. Nilanjan Roy, Chairperson, Independent Director
Prof. Catherine Rosenberg, Non-Executive Director
Ms. Manja Boerman, Independent Director
Mr. Suresh Narayanan, Independent Director
The Board, on January 22, 2019, constituted the Risk Management Committee in accordance with Regulation 21 of the SEBI Listing Regulations. The Risk Management Committee comprises of the following board members:
Mr. Nilanjan Roy, Chairman, Independent Director
Dr. Vijay Chandru, Independent Director
Ms. Manja Boerman, Independent Director
The Board, on October 21, 2021, constituted the Science and Technology Committee. The Science and Technology Committee comprises of the following board members:
Ms. Manja Boerman, Chairperson, Independent Director
Prof. Catherine Rosenberg, Non- Executive Director
Dr. Vijay Chandru, Independent Director
Dr. Arun Chandavarkar, Independent Director
Mr. Sanjaya Singh, Independent Director